

## **Expanding Access to Effective Treatment for Opioid Use Disorder: Provider Perspectives on Reducing Barriers to Evidence-Based Care**

National Press Club  
529 14<sup>th</sup> St NW, Washington, DC 20045  
September 20, 2018

Despite rising rates of opioid-related morbidity and mortality, millions of Americans still lack access to quality, evidence-based treatment for opioid use disorder (OUD). Although there is no “one size fits all” approach to treatment, there is strong evidence demonstrating the effectiveness of FDA-approved medications, including buprenorphine, methadone, and naltrexone, for OUD treatment. Supporting development, access, and adoption of medication-assisted treatment for OUD is a key priority of the U.S. Food and Drug Administration (FDA) as part of its response to the opioid crisis. However, substantial challenges remain in patient access and provider utilization of medications for OUD treatment.

The objective for this public workshop is to generate an active discussion with providers and health system stakeholders on the armamentarium of therapies to treat OUD, current barriers to appropriate use of these medications, and opportunities to further reduce stigma and expand access to effective pharmacotherapies as part of an evidence-based approach to OUD treatment.

**9:00 a.m. Welcome, Overview, and Meeting Objectives**

**Speakers:** Mark McClellan, Duke-Margolis Center for Health Policy  
Gregory Daniel, Duke-Margolis Center for Health Policy

**9:15 a.m. Opening Remarks**

**Speaker:** Janet Woodcock, U.S. Food and Drug Administration

**9:25 a.m. HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder**

**Speaker:** Brett Giroir, U.S. Department of Health and Human Services

**9:40 a.m. Patient-Focused Drug Development for Opioid Use Disorder**

**Speaker:** Sara Eggers, U.S. Food and Drug Administration

*Objective: Provide an overview of key findings from the FDA’s April 17 Public Meeting on Patient-Focused Drug Development for Opioid Use Disorder, including patient-reported experiences, challenges, and barriers to accessing or using medical treatments for OUD.*

**9:50 a.m. Understanding Opioid Use Disorder and the Treatment Armamentarium**

*Objective: Provide an overview of the current state of knowledge on addiction, clinical approaches for identification and assessment of OUD, and evidence supporting the use of medications for OUD treatment.*

**Presenters:**

- Edwin Salsitz, Mount Sinai Beth Israel
- Lisa Alexander, PA Education Association & George Washington School of Medicine and Health Services

**10:10 a.m.      Session I – Treatment for Opioid Use Disorder: Exploring Effective Approaches and Models of Care**

*Objective: Explore innovative and evidence-based approaches to OUD treatment delivery, identify lessons learned and challenges to broader implementation.*

**Moderator:** Mark McClellan, Duke-Margolis Center for Health Policy

**Presenters:**

- Colleen LaBelle, Boston Medical Center
- Kathryn Cates-Wessel, American Academy of Addiction Psychiatry
- Gail D’Onofrio, Yale Medicine
- Yngvild Olsen, Institute for Behavior Resources, Inc

**Moderated Discussion with Audience Q&A**

**11:15 a.m.      Break**

**11:30 a.m.      Session II – Examining Barriers to Access for Treatment of Opioid Use Disorder**

*Objective: Discuss legal, regulatory, and cultural barriers to access for treatment for opioid use disorder and identify potential opportunities to reduce stigma and expand access to effective OUD treatment.*

**Moderator:** Lawrence Greenblatt, Duke University School of Medicine

**Presenters:**

- Tom Hill, National Council for Behavioral Health
- Sharon Stancliff, New York State Department of Health
- Jessica Hulseley Nickel, Addiction Policy Forum
- Sarah Wattenberg, National Association for Behavioral Healthcare

**Moderated Discussion with Audience Q&A**

**12:35 p.m.      Lunch**

**1:35 p.m.      Session III – Opportunities and Barriers to Expand Treatment for Vulnerable Populations**

*Objective: Discuss care models and challenges for increasing access to OUD treatment for vulnerable and medically underserved populations.*

**Moderator:** Regina LaBelle, Duke-Margolis Center for Health Policy

**Presenters:**

- Marc Fishman, Maryland Treatment Centers
- Kaylin Klie, University of Colorado
- Kailee Fretland, Indian Health Service
- Jennifer Clarke, Rhode Island Department of Corrections

**Moderated Discussion with Audience Q&A**

**2:40 p.m.**      **Break**

**2:55 p.m.**      **Session IV – Future Directions for Treatment for Opioid Use Disorder: Defining Success and Identifying Outcomes that Matter**

*Objective: Discuss clinical, health system, and economic perspectives on defining successful outcomes for OUD treatment, including how establishing outcome measures may facilitate quality improvement, innovative payment approaches, and access to effective care.*

**Moderator:** Gregory Daniel, Duke-Margolis Center for Health Policy

**Presenters:**

- Alexander Walley, Boston Medical Center & Boston University School of Medicine
- Sarah Hudson Scholle, National Committee for Quality Assurance
- Mady Chalk, The Chalk Group
- Shawn Ryan, BrightView

**Moderated Discussion with Audience Q&A**

**4:00 p.m.**      **Closing Remarks**

**Speaker:** Mitra Ahadpour, U.S. Food and Drug Administration

**4:05 p.m.**      **Adjournment**

**Speaker:** Gregory Daniel, Duke-Margolis Center for Health Policy

*Funding for this workshop was made possible in part by a cooperative agreement with the Food and Drug Administration, Center for Drug Evaluation Research. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government.*